Cerner (CERN): Growth Slowing, Multiple Likely To Follow - UBS
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
UBS analyst, Michael Cherny, reiterated his Neutral rating on shares of Cerner (NASDAQ: CERN) but cut his price target to $60 from $66 after growth moderated as near term, 3Q’16 results were below expectation and longer term, the midpoint of preliminary 2017 revenue/EPS guidance was soft vs. consensus.
As the company faces the law of large numbers, multiples are likely to compress but the new PT equates to ~23x our FY17 EPS.
Shares of Cerner closed at $57.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bassett Furniture (BSET) PT Raised to $28 at Stifel Following 4Q EPS Beat
- Carter's (CRI) PT Lowered to $105 at Oppenheimer; Reiterates Outperform
- Polaris Industries (PII) PT Raised to $85 at Stifel Ahead of 4Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!